Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Rifampicin-Resistant Tuberculosis in Iran: A Systematic Review and Meta-Analysis Publisher



Bahraminia F1 ; Azimi T2 ; Zangiabadian M3 ; Nasiri MJ4 ; Goudarzi M4 ; Dadashi M5 ; Fooladi AAI1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Applied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
  2. 2. Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. 4. Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  5. 5. Department of Microbiology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran

Source: Iranian Journal of Basic Medical Sciences Published:2021


Abstract

Rifampicin (RIF)-resistant strain of Mycobacterium tuberculosis is an important barrier to effective tuberculosis (TB) treatment and prevention. The present study aimed to determine the frequency of RIF-resistant TB among patients with confirmed TB. Pubmed/Medline, Embase, Web of Science, and Scopus were searched for relevant articles published between January 1980 and January 2020. We pooled data with random-effects models when appropriate. After screening 1608 citations, 30 studies covering 8215 patients with TB were included. The pooled frequency of RIF-resistance among all patients with TB was 8.0% (95% CI 4.0–12.0). Our sub-group analysis showed that 4.0% of newly diagnosed cases and 36.0% of previously-treated TB patients from different settings in Iran were RIF-resistant. Our study showed that the frequency of RIF-resistance among patients with TB was 8.0%. Programmatic implementation of rapid drug susceptibility testing (DST) such as the Xpert MTB/RIF assay as a primary diagnostic test for persons suspected of having a RIF-resistant TB would be helpful for the control of the drug resistance. © 2021 Mashhad University of Medical Sciences. All rights reserved.
Related Docs
View other Related Docs
1. Isoniazid-Resistant Tuberculosis in Iran: A Systematic Review, Tuberculosis (2016)
2. First-Line Anti-Tubercular Drug Resistance of Mycobacterium Tuberculosis in Iran: A Systematic Review, Frontiers in Microbiology (2016)
3. Primary Ethambutol Resistance Among Iranian Pulmonary Tuberculosis Patients: A Systematic Review, Therapeutic Advances in Infectious Disease (2016)
4. The Reliability of Rifampicin Resistance As a Proxy for Multidrug-Resistant Tuberculosis: A Systematic Review of Studies From Iran, European Journal of Clinical Microbiology and Infectious Diseases (2018)
5. Mycobacterium Tuberculosis Complex Drug Resistance in a High Tuberculosis Incidence Area From the Who Eastern Mediterranean Region, Journal of Pharmacy and Pharmaceutical Sciences (2017)
6. Emerging and Re-Emerging Infectious Diseases in Iran, Iranian Journal of Microbiology (2017)
7. Drug Resistance Pattern of Mycobacterium Tuberculosis Isolates From Patients Referred to Tb Reference Laboratory in Ahvaz, Osong Public Health and Research Perspectives (2016)
8. Rifampicin Resistance in Mycobacterium Tuberculosis in Iran: A Two-Centre Study, New Microbes and New Infections (2021)
Experts (# of related papers)
View all Related Experts
Mohammad Mehdi Feizabadi (12)
Mehdi Yaseri (3)
Other Related Docs
9. Molecular Identification of Mutations Conferring Resistance to Rifampin, Isoniazid and Pyrazinamide Among Mycobacterium Tuberculosis Isolates From Iran, Journal of Chemotherapy (2020)
10. Low Diagnostic Accuracy of Xpert Mtb/Rif Assay for Extrapulmonary Tuberculosis: A Multicenter Surveillance, Scientific Reports (2019)
11. High-Resolution Melt Curve Analysis for Rapid Detection of Rifampicin Resistance in Mycobacterium Tuberculosis: A Single-Centre Study in Iran, New Microbes and New Infections (2020)
12. High Genetic Diversity Among Mycobacterium Tuberculosis Strains in Tehran, Iran, Journal of Clinical Tuberculosis and Other Mycobacterial Diseases (2018)
13. Rifampin Resistance Among Individuals With Extrapulmonary Tuberculosis: 4 Years of Experience From a Reference Laboratory, New Microbes and New Infections (2021)
14. Variation in Mycobacterium Tuberculosis Population Structure in Iran: A Systemic Review and Meta-Analysis, BMC Infectious Diseases (2021)
15. Global Status of Phenotypic Pyrazinamide Resistance in Mycobacterium Tuberculosis Clinical Isolates: An Updated Systematic Review and Meta-Analysis, Journal of Chemotherapy (2023)
16. Prevalence of and Risk Factors for Multidrug-Resistant Tuberculosis in Iran and Its Neighboring Countries: Systematic Review and Meta-Analysis, Revista da Sociedade Brasileira de Medicina Tropical (2017)
17. National Treatment Outcome and Predictors of Death and Treatment Failure in Multidrug-Resistant Tuberculosis in Ethiopia: A 10-Year Retrospective Cohort Study, BMJ Open (2021)
18. Efficacy of Line Probe Assay in Detection of Drug-Resistant Pulmonary Tuberculosis in Comparison With Genexpert and Phenotypic Methods in Iran and Genetic Analysis of Isolates by Miru-Vntr, Infection and Drug Resistance (2019)
19. Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium Tuberculosis, Frontiers in Microbiology (2021)
20. Genotyping and Drug Susceptibility Patterns of M. Tuberculosis Isolated From Hiv Seropositive Patients in Tehran Iran, Current HIV Research (2021)
21. Molecular Detection of Rifampin, Isoniazid, and Ofloxacin Resistance in Iranian Isolates of Mycobacterium Tuberculosis by High-Resolution Melting Analysis, Infection and Drug Resistance (2018)
22. An 8-Year Study on the Prevalence and Drug Resistance of Mycobacteria in Clinical Specimens (2011–2018), Clinical Epidemiology and Global Health (2020)
23. Performance of Wayne Assay for Detection of Pyrazinamide Resistance in Mycobacterium Tuberculosis: A Meta-Analysis Study, New Microbes and New Infections (2021)
24. Global, Regional, and National Burden of Tuberculosis, 1990-2016: Results From the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study, The Lancet Infectious Diseases (2018)
25. Can Interferon-Γ Release Assays Be Useful for Monitoring the Response to Anti-Tuberculosis Treatment?: A Systematic Review and Meta-Analysis, Archivum Immunologiae et Therapiae Experimentalis (2020)
26. Pattern of Drug Resistant Mycobacterium Tuberculosis in the West and Northwest of Iran: A Meta-Analysis, Iranian Journal of Microbiology (2022)
27. Screening for Streptomycin Resistance Conferring Mutations in Mycobacterium Tuberculosis Isolates From Iran, Journal of Chemotherapy (2017)
28. Direct Drug Susceptibility Testing of Mycobacterium Tuberculosis Using the Proportional Method: A Multicenter Study, Journal of Global Antimicrobial Resistance (2019)
29. Frequency of Mutational Changes in the Embb Among the Ethambutol-Resistant Strains of Mycobacterium Tuberculosis in Iran, Journal of Infection in Developing Countries (2016)
30. Genotyping and Drug Susceptibility Testing of Mycobacterium Tuberculosis in Iran: A Multi-Centre Study, New Microbes and New Infections (2020)
31. Genetic Diversity of Mycobacterium Tuberculosis Complex Isolates Circulating in an Area With High Tuberculosis Incidence: Using 24-Locus Miru-Vntr Method, Tuberculosis (2018)
32. Rapid Detection of Rifampicin- and Isoniazid-Resistant Mycobacterium Tuberculosis Using Taqman Allelic Discrimination, Osong Public Health and Research Perspectives (2016)
33. Mycobacterium Simiae Pulmonary Disease in Iran: Systematic Review and Meta-Analysis, New Microbes and New Infections (2018)
34. High Rates of Nontuberculous Mycobacteria Isolation From Patients With Presumptive Tuberculosis in Iran, New Microbes and New Infections (2018)
35. Miru-Vntr Analysis of Mycobacterium Tuberculosis From Tehran, Sistan-Baluchestan, Kermanshah and Hormozgan During 2014 and 2015, Cellular and Molecular Biology (2017)
36. The Targeted Maximum Likelihood Estimation to Estimate the Causal Effects of the Previous Tuberculosis Treatment in Multidrug-Resistant Tuberculosis in Sudan, PLoS ONE (2023)